Well, I subscribe to thestreet.com and have a lot of respect for the opinions they give, therefore, if they called you an "unabashed tout" and had the opportunity to have lengthy conversations with you, then I think we can safely assume that whatever you post should always be greeted with the same skepticism that any investor would give to any other "tout" or "shill". Which is too bad Henry, because you obviously are extremely knowledgable where LGND is concerned. Unfortunately, for those reading your posts they will in the future have to put them thru the "tout screen". You obviously have a huge financial stake in the success of LGND and therefore could never be considered an objective, though knowledgable, source. I had concerns regarding your bias earlier on and had posted a certain amount of skepticsm pointing to such and now I feel those concerns were justified.
As far as AMLN or LGND are concerned as investments, since I am not currently in either, I think I can say without a propensity toward neither, these are speculative plays at best and until either one can firmly establish themselves as an important weapon in the treatment of diabetes and other related illnesses, my point about considering the financial motivation of individuals such as yourself should be magnified. Leaving the merits of AMLN and LGND aside, Henry, I am amazed that you do not show any concern about your reputation being sullied by the article, but then perhaps you do not necessarily consider being called in print an "unabashed tout" something to be concerned about.
|
